Microdose Study Establishes Mass Balance of Elacytarabine - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Microdose Study Establishes Mass Balance of Elacytarabine

Quotient Clinical, a business unit of Quotient Bioresearch, announced the completion of a 14C microdose study with Clavis Pharma, to establish the mass balance of elacytarabine in healthy subjects. The clinical study was an open label, single-dose study to assess the mass balance recovery of an intravenous microdose of 14C-elacytarabine and involved the first dosing of elacytarabine, a cytotoxic molecule, to healthy male subjects.

The study requirement was driven by a request from the US Food and Drug Administration (FDA) to provide information on the routes of elimination of total radioactivity and total recovery.  By performing the study in healthy subjects, Clavis Pharma was able to avoid the complications of extended recruitment periods and potential inconsistency in compliance of a study in patients, according to a company press release.



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here